FindTrial
Sign In

Study on the efficacy and safety of plasmapheresis without plasma transfusion tandem in the treatment of mutiple myeloma

Study on the efficacy and safety of plasmapheresis without plasma transfusion tandem with chemotherapy in the treatment of mutiple myeloma

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100047507
Enrollment
Unknown
Registered
2021-06-20
Start date
2021-10-01
Completion date
Unknown
Last updated
2022-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mutiple Myeloma

Interventions

plasmapheresis without plasma transfusion combined with chemothreapy group:Nil
chemothreapy group:Nil

Sponsors

Taihe Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged 40 to 80 years, male and female; 2. Patients newly diagnosed with MM not treated with chemotherapy who meet diagnostic criteria for multiple myeloma; 3. Patient consent.

Exclusion criteria

Exclusion criteria: 1. Complicated with severe heart and lung failure; 2. With severe infection; 3. Coagulation dysfunction; 4. Combined thrombotic events: patients with arterial and venous thrombosis within 3 months; 5. Researcher determined not suitable to recuit.

Design outcomes

Primary

MeasureTime frame
Plasma globulin;Serum vascular endothelial growth factor (VEGF);Plasma IL-6;—

Secondary

MeasureTime frame
LDH;ß2-MG;Plasma creatinine;—

Countries

China

Contacts

Public ContactLi Zhangzhi

Taihe Hospital affiliate to Hubei University of Medicine

13872756573@163.com+86 13872756573

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026